Address
Email address
Phone number
Website
https://www.chemi-pharm.comChemi-Pharm | Allergen-Free Disinfection ProductsChemi-Pharm AS develops, produces and sells allergen-free disinfection agents, cleansing and skincare products and detergents. Learn more!
Name
Aktsiaselts CHEMI-PHARM
Registry code
10140819
VAT number
EE100310771
Type
AS - Joint Stock Company
Status
Registered
Foundation date
16.04.1997 (27)
Financial year
01.01-31.12
Capital
25 600.00 €
Activity
21201 - Manufacture of pharmaceutical preparations 74901 - Other professional, scientific and technical activities n.e.c. 46901 - Non-specialised wholesale trade 20411 - Manufacture of soap and detergents, cleaning and polishing preparations
-
-
-
-
-
-
-
No tax arrears
-
-
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Chemilex OÜ 16673409 | 30% - 7 680.00 EUR | - | - | Shareholder |
| Chemi-Pharm holding OÜ 16694950 | 70% - 17 920.00 EUR | - | - | Shareholder |
| Reza Yeganeh Khonsari
| - | Board member | - | |
| Ruth Oltjer
| - | Board member | - | |
| Britta Oltjer-Jaadla
| - | - | - | Board member |
| Gretta Oltjer-Timberg
| - | - | - | Board member |
| Merle Vacker
| - | - | - | Board member |
| Ivari Koppel
| - | - | - | Board member |
| Kristo Timberg
| - | - | - | Board member |
| Robert Kitt
| - | - | - | Board member |
| Andres Oltjer
| - | - | - | Chairman of the board |
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Osaühing ROSTHERNE 10449008 | 100% - 2 556.00 EUR | - | - | |
| PK Technologies OÜ 16328665 | 10% - 255.60 EUR | - | - | |
| Nordic Tersus Laboratory OÜ 12561442 | - | - | - | Founder |
| Osaühing Chemi-Pharm Group 10449072 | - | - | - | Founder |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q4 | 4 257 080.09 € | - | 305 916.15 € | 66 |
| 2024 Q3 | 3 613 009.08 € | 33 923.95 € | 274 456.35 € | 65 |
| 2024 Q2 | 3 969 449.66 € | 173 598.31 € | 279 548.16 € | 63 |
| 2024 Q1 | 4 095 121.41 € | 191 855.12 € | 293 387.59 € | 63 |
| 2023 Q4 | 3 919 378.17 € | 205 824.76 € | 248 835.19 € | 66 |
| 2023 Q3 | 3 324 732.14 € | 247 502.57 € | 260 675.96 € | 60 |
| 2023 Q2 | 3 556 786.29 € | 205 226.67 € | 266 320.2 € | 63 |
| 2023 Q1 | 3 537 638.43 € | 141 005.31 € | 289 445.06 € | 67 |
| 2022 Q4 | 3 636 025.6 € | 303 212.4 € | 284 354.72 € | 70 |
| 2022 Q3 | 3 529 352.82 € | 315 031.14 € | 292 656.97 € | 71 |
| 2022 Q2 | 4 680 873.32 € | 309 399.81 € | 300 260.42 € | 78 |
| 2022 Q1 | 4 450 489.11 € | 307 697.24 € | 313 110.04 € | 79 |
| 2021 Q4 | 4 906 264.97 € | 322 686 € | 279 983.54 € | 78 |
| 2021 Q3 | 3 638 392.1 € | 373 203.7 € | 294 336.56 € | 79 |
| 2021 Q2 | 4 675 374.75 € | 468 222.93 € | 291 190.35 € | 86 |
| 2021 Q1 | 5 295 234.82 € | 151 773.98 € | 314 381.5 € | 87 |
| 2020 Q4 | 6 142 676.77 € | 72 451.23 € | 249 035.83 € | 89 |
| 2020 Q3 | 5 809 136.52 € | 201 702.67 € | 245 091.57 € | 75 |
| 2020 Q2 | 5 873 634.12 € | 273 525.05 € | 227 056.01 € | 61 |
| 2020 Q1 | 2 235 537.09 € | 129 032.15 € | 173 885.28 € | 56 |
